About Prosetta Biosciences
Prosetta Biosciences is a company based in San Francisco (United States) founded in 2003. Prosetta Biosciences has raised $35.14 million across 7 funding rounds from investors including Takeda Pharmaceuticals, HHS and Alger. Prosetta Biosciences offers products and services including Small Molecule Therapeutics. Prosetta Biosciences operates in a competitive market with competitors including Moderna, Adaptive Biotechnologies, Chimerix, HOOKIPA Pharma and Novavax, among others.
- Headquarter San Francisco, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Prosetta Bio-Conformatics Private Limited
- Date of Incorporation 03 Mar, 2004
- Jurisdiction Mysore, Karnataka, India
-
Annual Revenue
$199.63 K (USD)12.46as on Mar 31, 2022
-
Net Profit
$24.89 K (USD)365.51as on Mar 31, 2022
-
EBITDA
$89.3 K (USD)12.76as on Mar 31, 2022
-
Total Equity Funding
$35.14 M (USD)
in 7 rounds
-
Latest Funding Round
$31.1 M (USD), Series D
Nov 20, 2015
-
Investors
Takeda Pharmaceuticals
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Prosetta Biosciences
Prosetta Biosciences offers a comprehensive portfolio of products and services, including Small Molecule Therapeutics.
Advances novel molecules to modulate protein complexes for disease therapy
People of Prosetta Biosciences
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Prosetta Biosciences
Prosetta Biosciences has successfully raised a total of $35.14M across 7 strategic funding rounds. The most recent funding activity was a Series D round of $31.1 million completed in November 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Prosetta Biosciences
Prosetta Biosciences has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Takeda Pharmaceuticals, HHS and Alger.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
ESG investments are managed by this venture capital firm.
|
Locked | Locked | Locked | |
|
Takeda Pharmaceuticals is engaged in developing innovative medicines globally.
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Prosetta Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Prosetta Biosciences
Investment portfolio details for Prosetta Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Prosetta Biosciences
Detailed financials for Prosetta Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Prosetta Biosciences Comparisons
Peer comparison for Prosetta Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Prosetta Biosciences
Prosetta Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Adaptive Biotechnologies, Chimerix, HOOKIPA Pharma and Novavax, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| Locked | Locked | Locked |
Antiviral oral therapeutics are developed for infectious diseases and cancers.
|
|
| Locked | Locked | Locked |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| Locked | Locked | Locked |
Novel vaccines are developed using nanoparticle and matrix adjuvant technology.
|
|
| Locked | Locked | Locked |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
Detailed competitors of Prosetta Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Prosetta Biosciences
Complete news archive for Prosetta Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Prosetta Biosciences
Prosetta Biosciences was founded in 2003 and raised its 1st funding round 4 years after it was founded.
Prosetta Biosciences is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Prosetta Biosciences is a funded company, having raised a total of $35.14M across 7 funding rounds to date.
Annual revenue of Prosetta Biosciences is $199.63K as on Mar 31, 2022.
Developer of antiviral and other therapeutics using proprietary drug discovery platform. The companys research is based on its proprietary cell-free protein synthesis or CFPSS drug discovery platform allows for the identification of small molecule drugs, which may be missed by traditional pharma screening methods. The company has successfully produced potent compounds which display activity against multiple strains of many viral families including lead series of molecules that are effective antiviral agents against influenza, HIV, and HCV.
Prosetta Biosciences's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
Prosetta Biosciences offers Small Molecule Therapeutics.
Prosetta Biosciences has 4 investors. Key investors include Takeda Pharmaceuticals, HHS, Alger, and Military Health.